The mission of Case Comprehensive Cancer Center (Case CCC), now in its 25th year of NCI designation, is to promote a coordinated, translational research-oriented culture of scientific discovery applied to human cancers, with dissemination to patients and populations to improve cancer prevention, detection, treatment, cure, and survivorship. The Center provides leadership and oversight of collaboration for basic cancer research oriented toward identification of novel therapeutic targets;prevention, control and population research;therapeutic and non-therapeutic clinical research across the disease spectrum;and community outreach. The Center coordinates all aspects of cancer research in Cleveland and Northern Ohio, including activities of the affiliate institutions of Case Western Reserve University School of Medicine: Cleveland Clinic and University Hospitals. The Center provides opportunities to participate in clinical trials to almost 10,000 cancer patients who are newly diagnosed annually in the region. The opening in 2011 of the new freestanding cancer hospital, UH Seidman Cancer Center, and the funding of the Gl SPORE represent major achievements in this past grant cycle. The Case CCC is organized around 8 Scientific Programs, 15 shared resources, and a clinical and behavioral cancer research infrastructure that prioritizes innovative translational research and investigator-initiated clinical trials that ut across the Scientific Programs. The Case CCC includes 232 full members (335 total members) from 5 schools and 30 academic departments who actively participate in Cancer Center activities including Program and Core meetings and retreats, leadership committees, and scientific focus groups, each promoting a transdisciplinary approach that facilitates discovery and clinical application. The Cancer focus of the Center is exceptional, with over $116M in total funding and over $45M in total NCI funding. Institutional commitment is also exceptional with over $115M dedicated to cancer research in the next cycle and over $350M in construction anticipated. The Case CCC and its affiliate institutions have established an outstanding infrastructure that enables its members to improve the prevention, diagnosis, and treatment of cancer through discovery, implementation and dissemination, while providing state-of-the-art care and treatment to cancer patients and their families. The Case CCC is a significant partner with the NCI in its effort to change the practice of cancer care through discovery and clinical research of the highest quality.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
5P30CA043703-24
Application #
8642144
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Ptak, Krzysztof
Project Start
Project End
Budget Start
Budget End
Support Year
24
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Levinson, Kimberly L; Jernigan, Amelia M; Flocke, Susan A et al. (2016) Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic Oncology Fellow Research Network Study. J Low Genit Tract Dis 20:47-51
Cooper, Gregory S; Kou, Tzuyung D; Schluchter, Mark D et al. (2016) Changes in Receipt of Cancer Screening in Medicare Beneficiaries Following the Affordable Care Act. J Natl Cancer Inst 108:
Wiechert, Andrew; Saygin, Caner; Thiagarajan, Praveena S et al. (2016) Cisplatin induces stemness in ovarian cancer. Oncotarget 7:30511-22
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2016) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev :
Kenyon, Jonathan; Nickel-Meester, Gabrielle; Qing, Yulan et al. (2016) Epigenetic Loss of MLH1 Expression in Normal Human Hematopoietic Stem Cell Clones is Defined by the Promoter CpG Methylation Pattern Observed by High-Throughput Methylation Specific Sequencing. Int J Stem Cell Res Ther 3:
Dowlati, A; Lipka, M B; McColl, K et al. (2016) Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol 27:642-7
Markowitz, Sanford D; Nock, Nora L; Schmit, Stephanie L et al. (2016) A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. PLoS One 11:e0146435
Wang, Y; Deng, O; Feng, Z et al. (2016) RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression. Oncogene 35:1363-72
Doherty, Mary R; Smigiel, Jacob M; Junk, Damian J et al. (2016) Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) 8:
Blum, Andrew E; Venkitachalam, Srividya; Guo, Yan et al. (2016) RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Res 76:5628-5633

Showing the most recent 10 out of 1148 publications